Literature DB >> 30862230

MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.

Ru-Jin Zhuang1, Xiao-Xu Bai1, Wei Liu1.   

Abstract

Ovarian cancer (OC) is xenogeneic that is influenced by many generated factors related to epigenetic factors to accelerate tumor metastasis. This study was conducted with the objective of investigating the effect of microRNA-23a-3p (miR-23a) on the biological characteristics of OC stem cells by targeting discs large homolog 2 (DLG2). OC-related differentially expressed genes were screened by microarray-based gene expression analysis, after which a list of miRNAs that regulate the genes was predicted. In total, 50 patients diagnosed with OC were enrolled in this study. DLG2 positive protein expression was measured in OC tissues. The interaction between DLG2 and miR-23a was predicted and analyzed through luciferase activity measurement. With the intervention of miR-23a and/or DLG2 expression in OC stem cells, the expression of miR-23a, DLG2, Bax, Bcl-2, Oct-4, and Nanog was determined. Afterward, different cell experiments were conducted to examine the regulation effect of miR-23a in OC stem cells. Tumor formation in vivo was also evaluated in nude mice. DLG2 had low expression in OC. The results showed that there was a decrease in the expression of Bcl-2, Oct-4, and Nanog, while DLG2 and Bax were increased as a result of miR-23a depletion. In addition, when miR-23a was suppressed, cell viability, migration, invasion, cloning, and renewal abilities of OC stem cells were decreased, while apoptosis ability was enhanced. As a target gene of miR-23a, DLG2 downregulation reversed the suppressive function of miR-23a in the inhibition of OC development. Finally, in vivo experiment verified that miR-23a downregulation restrained the tumor growth in OC stem cells. In conclusion, our findings suggested that the inhibition of miR-23a results in the suppression of OC progression by releasing DLG2, which provides new understanding on the potential therapeutic effect of miR-23a inhibition in OC patients.

Entities:  

Keywords:  MicroRNA-23a-3p; apoptosis; discs large homolog 2; ovarian cancer; tumor stem cells

Mesh:

Substances:

Year:  2019        PMID: 30862230      PMCID: PMC6605979          DOI: 10.1080/15384047.2019.1579960

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  35 in total

1.  miR-23a promotes the transition from indolent to invasive colorectal cancer.

Authors:  Sohail Jahid; Jian Sun; Robert A Edwards; Diana Dizon; Nicole C Panarelli; Jeffrey W Milsom; Shaheen S Sikandar; Zeynep H Gümüs; Steven M Lipkin
Journal:  Cancer Discov       Date:  2012-03-30       Impact factor: 39.397

Review 2.  Molecular characterization of ovarian cancer by gene-expression profiling.

Authors:  C Gómez-Raposo; M Mendiola; J Barriuso; D Hardisson; A Redondo
Journal:  Gynecol Oncol       Date:  2010-05-01       Impact factor: 5.482

3.  miR-23a, a critical regulator of "migR"ation and metastasis in colorectal cancer.

Authors:  Zhiwei Wang; Wenyi Wei; Fazlul H Sarkar
Journal:  Cancer Discov       Date:  2012-06       Impact factor: 39.397

Review 4.  MicroRNAs in the pathogenesis of cancer.

Authors:  Francesca Lovat; Nicola Valeri; Carlo M Croce
Journal:  Semin Oncol       Date:  2011-12       Impact factor: 4.929

5.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.

Authors:  Santosh Gupta; Kristiina Iljin; Henri Sara; John Patrick Mpindi; Tuomas Mirtti; Paula Vainio; Juha Rantala; Kalle Alanen; Matthias Nees; Olli Kallioniemi
Journal:  Cancer Res       Date:  2010-08-16       Impact factor: 12.701

Review 6.  Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases.

Authors:  Ravindresh Chhabra; Richa Dubey; Neeru Saini
Journal:  Mol Cancer       Date:  2010-09-03       Impact factor: 27.401

7.  [Inhibitory effects of puerarin on invasion and metastasis of oophoroma cells HO-8910].

Authors:  Jie Han; Chao-Qin Yu; Wei Shen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2009-07

8.  A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.

Authors:  Andrea Vecchione; Barbara Belletti; Francesca Lovat; Stefano Volinia; Gennaro Chiappetta; Simona Giglio; Maura Sonego; Roberto Cirombella; Elisa Concetta Onesti; Patrizia Pellegrini; Daniela Califano; Sandro Pignata; Simona Losito; Vincenzo Canzonieri; Roberto Sorio; Hansjuerg Alder; Dorothee Wernicke; Antonella Stoppacciaro; Gustavo Baldassarre; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-22       Impact factor: 11.205

9.  53BP1 suppresses tumor growth and promotes susceptibility to apoptosis of ovarian cancer cells through modulation of the Akt pathway.

Authors:  Shuhui Hong; Xiaoyan Li; Ying Zhao; Qifeng Yang; Beihua Kong
Journal:  Oncol Rep       Date:  2012-01-18       Impact factor: 3.906

10.  Differential expression of a new isoform of DLG2 in renal oncocytoma.

Authors:  Dmitry Zubakov; Zorica Stupar; Gyula Kovacs
Journal:  BMC Cancer       Date:  2006-04-26       Impact factor: 4.430

View more
  10 in total

1.  miR-1271 inhibits growth, invasion and epithelial-mesenchymal transition by targeting ZEB1 in ovarian cancer cells.

Authors:  Yanni Jiao; Guiping Zhu; Jiang Yu; Ying Li; Man Wu; Jing Zhao; Xiangwen Tian
Journal:  Onco Targets Ther       Date:  2019-08-28       Impact factor: 4.147

2.  Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.

Authors:  Simon Keane; Sophie Améen; Angelica Lindlöf; Katarina Ejeskär
Journal:  Cell Commun Signal       Date:  2020-04-20       Impact factor: 5.712

3.  Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma-Next-Generation Sequencing and Bioinformatics Approaches.

Authors:  Hsiang-Ying Lee; Yi-Jen Chen; Wei-An Chang; Wei-Ming Li; Hung-Lung Ke; Wen-Jeng Wu; Po-Lin Kuo
Journal:  Medicina (Kaunas)       Date:  2019-12-01       Impact factor: 2.430

4.  miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN.

Authors:  Zubiao Gao; Xiaofeng Ye; Anne Bordeaux; Stanka Hettich; Siyao Lin; Fang Han; Yan Jia
Journal:  Eur J Histochem       Date:  2021-02-04       Impact factor: 3.188

5.  GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1.

Authors:  Xin Ning; Guangyue Shi; Sujing Ren; Shuang Liu; Jing Ding; Ruichun Zhang; Lianwei Li; Qin Xie; Wei Xu; Fanling Meng; Rong Ma
Journal:  Oncologist       Date:  2022-02-03

6.  Inflammation suppresses DLG2 expression decreasing inflammasome formation.

Authors:  Simon Keane; Matthew Herring; Peter Rolny; Yvonne Wettergren; Katarina Ejeskär
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-02       Impact factor: 4.322

Review 7.  Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Authors:  Amoolya Kandettu; Divya Adiga; Vasudha Devi; Padmanaban S Suresh; Sanjiban Chakrabarty; Raghu Radhakrishnan; Shama Prasada Kabekkodu
Journal:  Genes Dis       Date:  2022-03-01

8.  bta-miR-23a Regulates the Myogenic Differentiation of Fetal Bovine Skeletal Muscle-Derived Progenitor Cells by Targeting MDFIC Gene.

Authors:  Xin Hu; Yishen Xing; Ling Ren; Yahui Wang; Qian Li; Qiyuan Yang; Min Du; Lingyang Xu; Luc Willems; Junya Li; Lupei Zhang
Journal:  Genes (Basel)       Date:  2020-10-20       Impact factor: 4.096

Review 9.  The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.

Authors:  Vu Hong Loan Nguyen; Chenyang Yue; Kevin Y Du; Mohamed Salem; Jacob O'Brien; Chun Peng
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

10.  Silencing of AKIP1 Suppresses the Proliferation, Migration, and Epithelial-Mesenchymal Transition Process of Glioma Cells by Upregulating DLG2.

Authors:  Zhaohui Chen; Haitao Wen; Jinwei Zhang; Xin Zou; Shuihua Wu
Journal:  Biomed Res Int       Date:  2022-01-24       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.